Federal Register / Vol. 75, No. 5 / Friday, January 8, 2010 / Notices 1029 

Defense Explosives Safety Board). The 

service of Mr. Bowling on the PRB has 

come to a close. His appointment was 

originally announced in the Federal 

Register of November 15, 2007 (72 FR 

64192). 

William B. Wark (CSB Board Member) 

continues to serve as the Chair of the 

PRB, as announced in the Federal 

Register of November 15, 2007 (72 FR 

64192). David Capozzi (Executive 

Director, United States Access Board) 

continues to serve as a Member of the 

PRB, as announced in the Federal 

Register of December 5, 2008 (73 FR 

74138). 

This notice is published in the 

Federal Register pursuant to the 

requirement of 5 U.S.C. 4314(c)(4). 

Dated: January 4, 2010. 

Christopher J. Kirkpatrick, 

Attorney-Advisor. 

[FR Doc. 2010–104 Filed 1–7–10; 8:45 am] 

BILLING CODE 6350–01–P 

DEPARTMENT OF COMMERCE 

National Oceanic and Atmospheric 

Administration 

RIN 0648–XT56 

Marine Mammals; File No. 14486 

AGENCY: National Marine Fisheries 

Service (NMFS), National Oceanic and 

Atmospheric Administration (NOAA), 

Commerce. 

ACTION: Notice; receipt of application. 

SUMMARY: Notice is hereby given that 

the Alaska SeaLife Center (ASLC), 301 

Railway Avenue, PO Box 1329, Seward, 

Alaska 99664–1329 (Dr. Ian Dutton, 

Responsible Party), has applied in due 

form for a permit to receive, import, and 

export marine mammal specimens for 

scientific research purposes. 

DATES: Written, telefaxed, or e-mail 

comments must be received on or before 

February 8, 2010. 

ADDRESSES: The application and related 

documents are available for review by 

selecting ‘‘Records Open for Public 

Comment’’ from the Features box on the 

Applications and Permits for Protected 

Species (APPS) home page, https:// 

apps.nmfs.noaa.gov, and then selecting 

File No. 14486 from the list of available 

applications. 

These documents are also available 

upon written request or by appointment 

in the following offices: 

Permits, Conservation and Education 

Division, Office of Protected Resources, 

NMFS, 1315 East-West Highway, Room 

13705, Silver Spring, MD 20910; phone 

(301)713–2289; fax (301)713–0376; and 

Alaska Region, NMFS, P.O. Box 

21668, Juneau, AK 99802–1668; phone 

(907)586–7221; fax (907)586–7249. 

Written comments on this application 

should be submitted to the Chief, 

Permits, Conservation and Education 

Division, at the address listed above. 

Comments may also be submitted by 

facsimile to (301)713–0376, or by email 

to NMFS.Pr1Comments@noaa.gov. 

Please include the File No. 14486 in the 

subject line of the email comment. 

Those individuals requesting a public 

hearing should submit a written request 

to the Chief, Permits, Conservation and 

Education Division at the address listed 

above. The request should set forth the 

specific reasons why a hearing on this 

application would be appropriate. 

FOR FURTHER INFORMATION CONTACT: 

Amy Sloan or Jennifer Skidmore, 

(301)713–2289. 

SUPPLEMENTARY INFORMATION: The 

subject permit is requested under the 

authority of the Marine Mammal 

Protection Act of 1972, as amended 

(MMPA; 16 U.S.C. 1361 et seq.), the 

regulations governing the taking and 

importing of marine mammals (50 CFR 

part 216), the Endangered Species Act of 

1973, as amended (ESA; 16 U.S.C. 1531 

et seq.), the regulations governing the 

taking, importing, and exporting of 

endangered and threatened species (50 

CFR 222–226), and the Fur Seal Act of 

1966, as amended (16 U.S.C. 1151 et 

seq.). 

The primary objective of this 

application is to support multiple 

ongoing research programs at the ASLC, 

including studies of population ecology, 

diet and nutrition, reproductive 

physiology, toxicology and health of 

marine mammals. The ASLC requests 

the annual collection, receipt, import 

and export of unlimited samples from 

4000 individual cetaceans and 5,000 

individual pinnipeds under NMFS 

jurisdiction for continued research on 

these species. Samples would be 

collected under existing permits in the 

countries of origin, would be the 

product of a legal subsistence hunt, 

incidental by-catch, routine husbandry/ 

medical examinations of public display 

animals in the U.S., or opportunistic 

carcass collection, or would be samples 

taken under other permitted research 

activities. No takes of live animals, 

direct or indirect, are requested in this 

application. ASLC requests the permit 

be issued for five years. 

In compliance with the National 

Environmental Policy Act of 1969 (42 

U.S.C. 4321 et seq.), an initial 

determination has been made that the 

activity proposed is categorically 

excluded from the requirement to 

prepare an environmental assessment or 

environmental impact statement. 

Concurrent with the publication of 

this notice in the Federal Register, 

NMFS is forwarding copies of the 

application to the Marine Mammal 

Commission and its Committee of 

Scientific Advisors. 

Dated: January 4, 2010. 

P. Michael Payne, 

Chief, Permits, Conservation and Education 

Division, Office of Protected Resources, 

National Marine Fisheries Service. 

[FR Doc. 2010–139 Filed 1–7–10; 8:45 am] 

BILLING CODE 3510–22–S 

DEPARTMENT OF COMMERCE 

International Trade Administration 

AGENCY: Department of Commerce. 

ACTION: Notice. 

Mission Statement 

Medical Trade Mission to India: 

March 8–13, 2010. 

Mission Description 

The United States Department of 

Commerce, International Trade 

Administration, U.S. and Foreign 

Commercial Service is organizing a 

Medical Trade Mission to New Delhi, 

Chennai and Mumbai, India, March 8– 

13, 2010. The Medical Trade Mission to 

India will include representatives of 

U.S. medical/healthcare industry 

manufacturers (equipment and devices 

including laboratory, emergency, 

diagnostic, physiotherapy, and 

orthopedic equipment, and healthcare 

information technology) and service 

providers. The mission will introduce 

U.S. suppliers to prospective end-users 

and partners whose needs and 

capabilities are targeted to each U.S. 

participant’s business objectives. The 

delegates will meet with Indian 

government officials to obtain first-hand 

information about regulations, policies 

and procedures and will visit healthcare 

facilities. The Commercial Service in 

India (CS India) will organize 

appointments and briefings in New 

Delhi, Chennai and Mumbai, India’s 

major healthcare industry hubs. U.S. 

participants will have the opportunity 

to interact with U.S. Embassy and 

Consulate officials and CS India 

healthcare specialists to discuss 

industry developments, opportunities, 

and marketing strategies. 

Medical Fair India, one of the largest 

medical tradeshows in India, coincides 

in time and location with the last stop 

of the Trade Mission. Trade Mission 

participants, therefore, can exhibit at the 


pwalker on DSK8KYBLC1PROD with NOTICES
1030 Federal Register / Vol. 75, No. 5 / Friday, January 8, 2010 / Notices 

tradeshow, in the U.S. Pavilion, as part 

of their program. Companies wishing to 

exhibit in the U.S. pavilion at the 

Medical Fair can register through the CS 

India office to receive a discount. 

Commercial Setting 

The Indian healthcare industry is 

experiencing a rapid transformation and 

is emerging as a promising market for 

U.S. suppliers of high-end products. 

The Indian healthcare market, currently 

at $35 billion annually, is expected to 

reach more than $75 billion annually by 

2012. The growth in affluence of more 

than 300 million middle-income 

consumers is creating demand for 

higher standards of healthcare. The 

changing demographic profile and the 

rise of lifestyle-related diseases have 

altered the health seeking behavior of 

the consumer. While private insurance 

covers only 10% of the populations, 

coverage is growing at 40% per year. 

The medical infrastructure in India is 

insufficient for the population, with 

demand for hospitals and beds far 

exceeding supply. The problem is acute 

in rural India, which accounts for over 

half of India’s population, while about 

80 percent of available hospital beds are 

located in the urban centers. Both 

government and private operators have 

major expansion plans to meet demand 

and increase quality. Healthcare in India 

is provided through primary care 

facilities and secondary and tertiary care 

hospitals. While the public sector 

provides primary and secondary care, 

tertiary care hospitals are owned and 

managed by both government and 

private sector. Over the next 5–6 years, 

150–200 tertiary hospital projects are 

expected to be constructed, including 

hospitals of varying capacities. Most 

Indian healthcare facilities use imported 

medical equipment for diagnosis, 

treatment and surgery with over 35% of 

the imports coming from the U.S. New 

specialty and super-specialty hospitals 

depend on the import of high-end 

medical equipment for over 65 percent 

of their needs, and this sector is growing 

at a rate of 15 percent annually. 

Medical tourism is one of the major 

external drivers of growth in India’s 

healthcare sector. India treated 450,000 

foreign patients in 2007 and the 

expected increase in this sector is 

contributing to improved quality 

controls. India’s National Accreditation 

Board for Hospitals (NABH) operates 

accreditation programs for healthcare 

organizations. Some private hospitals 

are also applying for certification from 

international accreditation organizations 

such as the Joint Commission 

International (JCI). Accreditation by 

NABH and JCI has ensured better 

standards of healthcare in hospitals. 

Mission Goals 

The goal of the Medical Trade 

Mission to India is to (1) familiarize the 

U.S. companies with the current 

healthcare situation as well as the 

developments taking place; (2) 

introduce U.S. companies to appropriate 

government officials in India to learn 

about various regulatory procedures and 

policies; and (3) introduce companies to 

potential end-users, representatives and 

partners. 

Mission Scenario 

The first stop on the mission itinerary 

is New Delhi, the capital. In meetings 

with representatives of the Ministry of 

Health, Drug Controller General Office, 

and Department of Pharmaceuticals, the 

U.S. mission members will learn about 

policies, regulations and opportunities 

in the country’s healthcare industry, 

such as expansion plans of the Fortis 

and Max hospital groups. 

Chennai and Mumbai are the second 

and third stops of the mission, located 

in southern and western India 

respectively. Several corporate hospital 

chains have their headquarters in these 

cities. These include the Apollo Group 

in Chennai, and Wockhard and the Tata 

Institute of Fundamental Research in 

Mumbai. 

The three cities on the mission 

itinerary are the regional hubs for the 

Indian medical/healthcare industry. 

End-users often prefer to be serviced by 

regional distributors/agents based in 

these cities, rather than country-wide 

distributors. In all three cities the 

delegates will attend U.S. Embassy or 

Consulate industry briefings and take 

part in networking events and business 

matchmaking appointments. 

Participation in the mission will include 

the following: 

• Pre-travel briefings/webinars on 

subjects including business practices in 

India and specifics on the medical/ 

healthcare industry; 

• Embassy/Consulate briefings on the 

business climate, political scenario, and 

medical/healthcare industry in New 

Delhi, Chennai and Mumbai; 

• Pre-scheduled meetings with 

potential partners, distributors, endusers, or local industry contacts in New 

Delhi, Chennai and Mumbai; 

• Meetings with Indian Government 

officials; 

• Tour of public and private hospitals 

and interaction with senior hospital 

staff; 

• Networking receptions in three 

cities of the trade mission; 

• Built-up 9sq meter exhibitor booth * 

in the U.S. Pavilion at Medical Fair 

India, Mumbai. (Option two only.) 

* Contact us for price of booth. 

Proposed Mission Timetable 

Mission participants will be 

encouraged to arrive Saturday, March 6, 

2010 to allow time to adjust to their new 

surroundings before the mission 

program begins on Monday, March 8. 

Monday, March 8 ............... New Delhi 

Embassy briefing by U.S. Departments of Commerce and State Meetings with Government of India ministries. 

One-on-one business appointments. 

Evening: Networking reception. 

Tuesday, March 9 .............. New Delhi/Chennai 

Industry briefing. 

One-on-one business appointments. 

Hospital or other site visit. 

Check-out of the hotel. 

Evening flight to Chennai. 

Wednesday, March 10 ....... Chennai 

Breakfast briefing by the U.S. Commercial Service at hotel. 

Hospital visit and meeting with senior management, including the procurement executives. 

One-on-one business appointments. 

Evening: Networking reception. 

Thursday, March 11 ........... Chennai/Mumbai 

One-on-one business appointments. 

Check-out of the hotel. 

Afternoon flight to Mumbai. 

Friday, March 12 ................ Mumbai 


pwalker on DSK8KYBLC1PROD with NOTICES
Federal Register / Vol. 75, No. 5 / Friday, January 8, 2010 / Notices 1031 

1An SME is defined as a firm with 500 or fewer 

employees or that otherwise qualifies as a small 

business under SBA regulations (see http:// 

www.sba.gov/services/contracting_opportunities/ 

sizestandardstopics/index.html). Parent companies, 

affiliates, and subsidiaries will be considered when 

determining business size. The dual pricing 

schedule reflects the Commercial Service’s user fee 

schedule that became effective May 1, 2008 (for 

additional information see http://www.export.gov/ 

newsletter/march2008/initiatives.html). 

2Minimum booth space is 9 square meters. 

Companies can take larger space for which cost will 

be calculated accordingly. 

1The petitioners are the United States Steel 

Corporation Steel, Nucor Corporation, and 

ArcelorMittal USA Inc. (collectively ‘‘petitioners’’). 

Breakfast briefing by the U.S. Commercial Service at hotel. 

One-on-one business appointments or exhibition at Medical Fair India. 

Evening: Networking reception. 

Saturday, March 13 ............ Mumbai 

Hospital chain visit and meeting with senior management. 

Or Medical Fair India 2010. 

Evening: Check-out of the hotel or remain in Mumbai for Medical Fair India. 

Depart for Mumbai International airport for onward travel. 

Participation Requirements 

All parties interested in participating 

in the Medical Trade Mission to India 

must complete and submit an 

application for consideration by the 

Department of Commerce. All 

applicants will be evaluated on their 

ability to meet certain conditions and 

best satisfy the selection criteria as 

outlined below. The mission is open on 

a first come first served basis to 15 

qualified U.S. companies. Additional 

applications will be considered as time 

and space permits. 

Fees and Expenses 

After a company has been selected to 

participate on the mission, a payment to 

the Department of Commerce in the 

form of a participation fee is required. 

The participation fees reflect two 

options: 

Option 1: March 8–13, 2010. 

Participation in the Trade Mission in all 

three cities: New Delhi, Chennai, and 

Mumbai. The participation fee will be 

$4,600 for large firms and $3,900 for a 

small or medium-sized enterprise 

(SME) 1, this includes one principal 

representative. The fee for each 

additional firm representative (large 

firm or SME) is $500. 

Option 2: March 8–11, 2010 

participate in the Trade Mission in two 

cities: New Delhi and Chennai and 

March 12–14, exhibit at the Medical 

Fair India 2010 in Mumbai. The 

participation fee for New Delhi-Chennai 

and exhibiting in the Fair in Mumbai 

$6,800 ($3,600 Trade Mission fee + 

$3,200 for 9 square meter booth space 2) 

for large firms and $ 6,100 ($2,900 Trade 

Mission fee + $3,200 for 9 square meter 

booth space) for an SME, which 

includes one principal representative. 

The fee for each additional firm 

representative (large firm or SME) is 

$250. 

Expenses for lodging, some meals, 

incidentals, and travel (except for 

transportation to and from meetings) 

will be the responsibility of each 

mission participant. 

Conditions for Participation 

• An applicant must submit a 

completed and signed mission 

application and supplemental 

application materials, including 

adequate information on the company’s 

products and/or services, primary 

market objectives, and goals for 

participation. 

• Each applicant must also certify 

that the products and services it seeks 

to export through the mission are either 

produced in the United States, or, if not, 

marketed under the name of a U.S. firm 

and have at least fifty-one percent U.S. 

content. 

Selection Criteria for Participation 

Selection will be based on the 

following criteria: 

• Suitability of a company’s products 

or services to the mission’s goals. 

• Applicant’s potential for business 

in India, including likelihood of exports 

resulting from the trade mission. 

• Consistency of the applicant’s goals 

and objectives with the stated scope of 

the trade mission. 

Any partisan political activities 

(including political contributions) of an 

applicant are entirely irrelevant to the 

selection process. 

Timeframe for Recruitment and 

Applications 

Mission recruitment will be 

conducted in an open and public 

manner, including posting in the 

Federal Register, the Commerce 

Department trade mission calendar 

(http://www.ita.doc.gov/doctm/ 

tmcal.html), and other Internet Web 

sites; press releases to general and trade 

media; direct mail; notices by industry 

trade associations and other multiplier 

groups; and publicity at industry 

meetings, symposia, conferences, and 

trade shows. Recruitment for the 

mission will begin immediately and 

conclude no later than January 31, 2010. 

Contacts 

U.S. Commercial Service Healthcare 

Team: Ms. Jetta DeNend, International 

Trade Specialist, U.S. Commercial 

Service, 33 Whitehall St. 22nd Floor, 

New York, NY 10004, Ph: 212–809– 

2644/Fax: 212–809–268, E-mail: 

Jetta.DeNend@mail.doc.gov. 

U.S. Commercial Service in India: Mr. 

Srimoti Mukherji, U.S. Commercial 

Service, New Delhi, Ph: 91–11– 

23472000, ext 2226, Fax: 91–11–2331 

5172, Srimoti.Mukherji@mail.doc.gov. 

Lisa Huot, 

Global Trade Programs, Commercial Service 

Trade Missions Program. 

[FR Doc. 2010–108 Filed 1–7–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF COMMERCE 

International Trade Administration 

(A–533–820) 

Certain Hot–Rolled Carbon Steel Flat 

Products from India: Notice of 

Preliminary Results of Antidumping 

Duty Administrative Review, and Intent 

to Rescind in Part 

AGENCY: Import Administration, 

International Trade Administration, 

Department of Commerce. 

SUMMARY: In response to requests from 

petitioners,1 the Department of 

Commerce (‘‘the Department’’) is 

conducting an administrative review of 

the antidumping order on certain hot– 

rolled carbon steel flat products from 

India (‘‘Indian Hot–Rolled’’) 

manufactured by Essar Steel Limited 

(‘‘Essar’’), Ispat Industries Limited 

(‘‘Ispat’’), JSW Steel Limited (‘‘JSW’’), and 

Tata Steel Limited (‘‘Tata’’). The period 

of review (‘‘POR’’) covers December 1, 

2007, through November 30, 2008. We 

preliminarily determine to calculate an 

antidumping duty margin based upon 

the application of adverse facts available 

(‘‘AFA’’) with respect to Essar’s sales. 

We also preliminarily determine that 

Ispat, JSW and Tata had no entries of 

subject merchandise subject to review 

under this antidumping order during 


pwalker on DSK8KYBLC1PROD with NOTICES